Among the suffering names in the stock market after the close Wednesday was
, which slid nearly 4% amid generally mixed late trading.
The auto-finance firm lost most of today's big run-up gains even though it made 66 cents a share in the fiscal fourth quarter to top estimates by 4 cents, per Thomson Financial. Revenue, at $625.4 million, was just shy of the average target. Shares gave back 79 cents to $20.
slumped 6.4% after the microturbine-technology developer said fiscal first-quarter revenue sank 14.5% year over year to $5.6 million. Despite also narrowing its per-share loss by 2 cents to 7 cents a share, the Chatsworth, Calif., company was off 7 cents to $1.03.
shed 4.1% after the oil-and-gas driller offered $500 million in contingent convertible senior bonds. Biotech
lost 3.4% to $3.70, after booking regular-session gains on a sharply narrowed second-quarter loss -- 3 cents a share from 60 cents last year.
, a Plainsville, Ind., wireless-device distributor, said earnings before interest, taxes, depreciation and amortization fell by 16.6% vs. last year to $12.1 million. Per-share earnings nearly doubled to 35 cents and revenue was markedly higher, but shares were still losing 7.4% in a pullback from an intense regular-session run-up.
Among the postbell winners was
American Oriental Bioengineering
. Shares of the China-based biotech flew 8.7% higher after second-quarter income came to $9.7 million, or 15 cents a share, on 49% higher revenue of $33.9 million. A year ago the company made $5.8 million, or 9 cents a share.
AOB also said it signed a letter of intent to buy Guangxi Boke Pharmaceutical for some $40 million. The expected all-cash deal should close by the end of the third quarter. AOB shares were up 72 cents to $9.